Komipharm International Co. Ltd (041960) - Total Assets
Based on the latest financial reports, Komipharm International Co. Ltd (041960) holds total assets worth ₩133.65 Billion KRW (≈ $90.57 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Komipharm International Co. Ltd for net asset value and shareholders' equity analysis.
Komipharm International Co. Ltd - Total Assets Trend (2011–2024)
This chart illustrates how Komipharm International Co. Ltd's total assets have evolved over time, based on quarterly financial data.
Komipharm International Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Komipharm International Co. Ltd's total assets of ₩133.65 Billion consist of 48.8% current assets and 51.2% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 10.1% |
| Accounts Receivable | ₩15.70 Billion | 12.8% |
| Inventory | ₩14.57 Billion | 11.9% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩3.89 Billion | 3.2% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Komipharm International Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 041960 stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Komipharm International Co. Ltd's current assets represent 48.8% of total assets in 2024, an increase from 0.0% in 2011.
- Cash Position: Cash and equivalents constituted 10.1% of total assets in 2024, down from 18.8% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 12.8% of total assets.
Komipharm International Co. Ltd Competitors by Total Assets
Key competitors of Komipharm International Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Theragen Etex Co.Ltd
KQ:066700
|
Korea | ₩245.25 Billion |
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250
|
Korea | ₩529.96 Billion |
|
ST Pharm Co.Ltd
KQ:237690
|
Korea | ₩782.57 Billion |
|
Oscotec Inc
KQ:039200
|
Korea | ₩154.14 Billion |
|
Caregen Co.Ltd
KQ:214370
|
Korea | ₩233.98 Billion |
|
NatureCell Co.Ltd
KQ:007390
|
Korea | ₩71.32 Billion |
|
Mezzion Pharma Co.Ltd
KQ:140410
|
Korea | ₩87.88 Billion |
|
Huons Global Co. Ltd
KQ:084110
|
Korea | ₩1.47 Trillion |
Komipharm International Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.03 | 1.31 | 1.14 |
| Quick Ratio | 1.58 | 0.99 | 0.78 |
| Cash Ratio | 0.00 | 0.52 | 0.00 |
| Working Capital | ₩35.07 Billion | ₩16.52 Billion | ₩5.34 Billion |
Komipharm International Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Komipharm International Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.88 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 3.5% |
| Total Assets | ₩122.77 Billion |
| Market Capitalization | $380.81 Million USD |
Valuation Analysis
Below Book Valuation: The market values Komipharm International Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Komipharm International Co. Ltd's assets grew by 3.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Komipharm International Co. Ltd (2011–2024)
The table below shows the annual total assets of Komipharm International Co. Ltd from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩122.77 Billion ≈ $83.20 Million |
+3.52% |
| 2023-12-31 | ₩118.60 Billion ≈ $80.37 Million |
+6.13% |
| 2022-12-31 | ₩111.75 Billion ≈ $75.73 Million |
-3.05% |
| 2021-12-31 | ₩115.26 Billion ≈ $78.11 Million |
-5.46% |
| 2020-12-31 | ₩121.91 Billion ≈ $82.62 Million |
-2.97% |
| 2019-12-31 | ₩125.64 Billion ≈ $85.15 Million |
-10.19% |
| 2018-12-31 | ₩139.90 Billion ≈ $94.81 Million |
-6.27% |
| 2017-12-31 | ₩149.27 Billion ≈ $101.16 Million |
-0.38% |
| 2016-12-31 | ₩149.84 Billion ≈ $101.55 Million |
+12.34% |
| 2015-12-31 | ₩133.39 Billion ≈ $90.40 Million |
+7.23% |
| 2014-12-31 | ₩124.40 Billion ≈ $84.30 Million |
+14.34% |
| 2013-12-31 | ₩108.80 Billion ≈ $73.73 Million |
+41.34% |
| 2012-12-31 | ₩76.98 Billion ≈ $52.17 Million |
+20.06% |
| 2011-12-31 | ₩64.12 Billion ≈ $43.45 Million |
-- |
About Komipharm International Co. Ltd
Komipharm International Co., Ltd. manufactures and sells veterinary vaccines, veterinary pharmaceuticals and disinfectants, and bio-fertilizers internationally. It also develops anticancer drugs and pain-relieving agents, which include Kominox, an arsenic-based oral drug; and Panaphix, a non-narcotic cancer pain reliever, as well as provides clinical pathological experiment, test, and analysis se… Read more